Updated Clinical Variants of Atopic Dermatitis
Atopic dermatitis manifests in distinct age-specific distribution patterns and several recognized clinical variants beyond the classic presentation, including lichenoid, nummular, follicular, prurigo nodularis, juvenile plantar dermatosis, and psoriasiform variants.
Age-Specific Distribution Patterns
The most fundamental clinical variants are defined by age and anatomic distribution 1:
Infancy
- Facial and extensor involvement is characteristic
- Lesions typically start on the cheeks and extend to neck, trunk, and extensor surfaces of extremities
- Notable sparing of the diaper area is a key diagnostic feature
- Duration must exceed 2 months for diagnosis
Childhood and Adolescence
- Flexural surfaces become predominantly affected
- More localized and chronic presentation
- Lesions commonly involve antecubital and popliteal fossae
- Duration must exceed 6 months for diagnosis
Adults
- Current or prior flexural involvement remains characteristic
- Consistent sparing of groin and axillary regions across all age groups 2
Recognized Clinical Variants
Beyond age-specific patterns, several distinct morphologic variants are now recognized 3:
Lichenoid Atopic Dermatitis
- Presents with thickened, lichenified plaques
- Results from chronic scratching and rubbing
- More common in chronic disease phases
Nummular-Type Atopic Dermatitis
- Coin-shaped eczematous patches
- Can be confused with nummular eczema
- Dupilumab has demonstrated specific efficacy for this phenotype 4
Follicular Atopic Dermatitis
- Perifollicular accentuation of lesions
- More common in darker skin types
- May present with prominent follicular papules
Prurigo Nodularis Phenotype
- Discrete, intensely pruritic nodules
- Associated with chronic scratching behavior
- Both cyclosporine and dupilumab show effectiveness for this variant 4
- Nemolizumab specifically targets IL-31 and is particularly effective 5
Juvenile Plantar Dermatosis
- Affects weight-bearing areas of feet
- Shiny, glazed appearance with fissuring
- Seen primarily in children
Hand Eczema Variant
- Localized to hands with chronic, hyperkeratotic changes
- Alitretinoin demonstrates particular efficacy for hand-predominant disease 4
- Ineffective for other anatomic locations
Psoriasiform Atopic Dermatitis
- Overlapping features with psoriasis
- Thicker, more demarcated plaques than typical AD
Less Common Variants
- Perineal dermatitis
- Perioral and periauricular involvement
- Lip licker's dermatitis
- Eczema coxsackium (viral-triggered variant)
- Alopecia associated with scalp involvement 3
Immunologic Endotypes
Modern understanding recognizes that AD phenotypes correlate with variable immune pathway involvement 1:
Acute Phase
- Th2-dominant with IL-4, IL-5, IL-13, IL-31 elevation
- Characterized by erythema, exudation, papules, vesiculopapules
Chronic Phase
- Th1 response activation with IFN-γ, IL-12 expression
- Th17/IL-17 involvement in epidermal proliferation and thickening
- Th22/IL-22 production inducing acanthosis
- Manifests as lichenification, prurigo, scales, crusts
Clinical Implications for Treatment
Treatment selection should consider the specific phenotype 4:
- Dupilumab: Effective across phenotypes, particularly rapid response when flexural folds involved, proven efficacy in prurigo nodularis and nummular variants
- Cyclosporine: Broad efficacy, particularly effective for prurigo nodularis phenotype
- Alitretinoin: Highly specific for hand eczema variant, ineffective elsewhere
- Nemolizumab: Targets IL-31, particularly effective for prurigo nodularis with severe pruritus 5
Important Diagnostic Considerations
Common pitfalls to avoid:
- In infancy, AD can overlap with seborrheic dermatitis; however, AD spares groin/axillae while seborrheic dermatitis affects these areas and lacks significant pruritus 2
- Failure to respond to standard therapy should prompt reconsideration of diagnosis, including immunodeficiencies in children or cutaneous T-cell lymphoma in adults 2
- Allergic contact dermatitis may coexist with AD and exacerbate symptoms 2
The recognition of these distinct clinical variants and their correlation with specific immunologic endotypes represents a shift toward personalized medicine in AD management 6, moving away from the traditional "one-size-fits-all" approach toward phenotype-directed therapy selection.